CoChat

Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti‐diabetic medication: a follow‐up study

Open access
Wenten, M., Gaebler, J. A., Hussein, M., Pelletier, E. M., Smith, D. B., Girase, P., Noel, R. A., Braun, D. K., Bloomgren, G. L. · 2012 · Diabetic Medicine
Cited by 75

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Aims Previously, a retrospective cohort study found no increased risk of acute pancreatitis with current or recent use of exenatide twice daily compared with use of other anti‐diabetic drugs. This follow‐up study investigated incident acute pancreatitis, with the use of a different data source and analytic method, in patients exposed to exenatide twice daily compared with patients exposed to other anti‐diabetic medications. Methods A large US health insurance claims database was used. Eligible patients had ≥ 9 months continuous enrollment without a claim for pancreatitis and a claim for a new anti‐diabetic medication on or after 1 June 2005 to 31 March 2009. Cases of acute pancreatitis were defined as hospitalized patients with an Internation Classification of Disease 9 code of 577.0 in the primary position. A discrete time survival model was used to evaluate the relationship between exenatide twice daily and acute pancreatitis. Results Of 482 034 eligible patients, 24 237 initiated exenatide twice daily and 457 797 initiated another anti‐diabetic medication. Initiators of exenatide twice daily had more severe diabetes compared with initiators of other anti‐diabetic medications. After adjustments for propensity score, insulin and use of medication potentially associated with acute pancreatitis, the odds ratio with exenatide twice daily exposure was 0.95 (95% CI 0.65–1.38). A secondary analysis that examined current, recent and past medication exposure found no increased risk of acute pancreatitis with exenatide twice daily, regardless of exposure category. Conclusion This study indicates that exposure to exenatide twice daily was not associated with an increased risk of acute pancreatitis compared with exposure to other anti‐diabetic medications. These results should be interpreted in light of potential residual confounding and unknown biases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2012.03652.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 75

Metadata

Authors
Wenten, M., Gaebler, J. A., Hussein, M., Pelletier, E. M., Smith, D. B., Girase, P., Noel, R. A., Braun, D. K., & Bloomgren, G. L.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2012-10-08
Volume
29
Issue
11
Pages
1412-1418
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W1565699562
Cited by
75
References
2
FWCI
11.74
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti‐diabetic medication: a follow‐up study. https://app.cochat.ai/papers/10.1111/j.1464-5491.2012.03652.x
The paper
Wenten, M., Gaebler, J. A., Hussein, M., Pelletier, E. M., Smith, D. B., Girase, P., Noel, R. A., Braun, D. K., & Bloomgren, G. L. (2012). Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti‐diabetic medication: a follow‐up study. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2012.03652.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.